Yep, Swami indirectly mentioned that the DFU trial is caput and they weren't getting an improvement over competitors because clinicians were using it the same way (as a dressing?) instead of how it was intended. So now they have reoriented the approach to in patient "limb salavage" with operative debridment and BTM application to create a wound bed with good vascularity. Lots of those patients would likely be diabetic patients or vasculopaths. We are not in the oupatient clinic dressing business.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.22 |
Change
0.015(1.24%) |
Mkt cap ! $842.8M | |||
| Open | High | Low | Value | Volume |
| $1.20 | $1.22 | $1.19 | $2.606M | 2.146M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 37701 | $1.20 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.22 | 102533 | 4 |
View Market Depth
| Last trade - 16.10pm 20/06/2025 (20 minute delay) ? |
| PNV (ASX) Chart |